Top 10 Biotechnology Companies in New York

By on

Abstract colorful art representing Biotechnology in New York

Explore the top 10 Biotechnology companies in New York (in the ConnectFlux database) by estimated revenue ranges. These industry leaders are making significant contributions to the market and shaping the future of Biotechnology.

1. Gotham Therapeutics

Gotham Therapeutics is an innovative biotechnology company located in the heart of New York, New York. Specializing in epitranscriptomics, which focuses on the biochemical modifications of RNA, Gotham is reshaping how we understand gene expression and its impact on health. Their cutting-edge services aim to create groundbreaking therapeutic interventions using small molecule drugs that target RNA-modifying proteins, offering hope to patients battling cancers, autoimmune disorders, and neurodegenerative diseases. What sets Gotham apart is its holistic, 360-degree approach to drug design, utilizing advanced, biophysics-driven methods for fragment-based drug discovery. Collaborating with top-tier partners like ZoBio, they've achieved remarkable milestones, including identifying lead candidates for the METTL3/METTL14 complex—an essential target in epitranscriptomics. Since the company's inception, Gotham Therapeutics has made significant strides in the biotechnology landscape, proving the effectiveness of its semi-virtual model and strong partnerships with leading CROs. Situated in New York, Gotham is deeply committed to enhancing life sciences within a vibrant research ecosystem. By leveraging its expertise in epitranscriptomics, Gotham Therapeutics is not just serving its clients; it’s revolutionizing therapeutic solutions for previously unmet medical needs, making a lasting impact on the biotechnology and research sectors. For more insights into their pioneering work, check out this research article.

Research, Research, Biotechnology research
Founded in 2017
New York, New York

2. Artemis Therapeutics, Inc.

Artemis Therapeutics, Inc. is revolutionizing holistic health with its innovative approach to natural sinus support and stress management, all backed by solid science. Founded by passionate holistic health practitioners, this company stands out in the biotechnology research scene, offering thoughtfully crafted plant-based solutions that resonate with health-conscious individuals everywhere. Although not based in New York, New York, Artemis Therapeutics has carved out a significant niche in the healthcare landscape, gaining traction and recognition across various regions. Its presence on major financial platforms highlights its vital role in the biotech industry, showcasing a commitment to holistic practices that truly set it apart. By emphasizing mind-body wellness, Artemis Therapeutics aligns seamlessly with modern healthcare trends that favor natural, scientifically-backed solutions. This focus is evident in the research pipelines of leading pharmaceutical companies. By delivering effective and sustainable health support, Artemis Therapeutics meets the growing demand for comprehensive care, making it a key player in both the biotech and healthcare sectors. If you want to explore more about their innovative solutions, check out this [resource](https://www.ncbi.nlm.nih.gov) that discusses the importance of holistic health in today's world.

Research, Research, Biotechnology research
Founded in 2009
New York, New York

3. FourStar Microbial Products, LLC

FourStar Microbial Products, LLC is revolutionizing the biotechnology and mosquito control landscape with its cutting-edge microbial solutions that tackle mosquito larvae head-on. Imagine a world where eco-friendly products not only protect your backyard but also safeguard our precious aquatic ecosystems; that’s exactly what FourStar offers with its innovative microbial larvicides. By harnessing the power of naturally occurring bacteria like Bacillus sphaericus (Bsph) and Bacillus thuringiensis israelensis (Bti), their products effectively target mosquitoes while being safe for humans, livestock, and wildlife alike. A standout feature of FourStar’s offerings is their patented dual-action sustained release technology, which provides long-lasting control, meaning fewer treatments and reduced labor costs—talk about a win-win! Products like FourStar CRG and FourStar Briquets exemplify this technology, ensuring that mosquito control programs can efficiently manage breeding sites with ease. Although specific details about the company’s local impact in Sag Harbor, New York, might be sparse, their commitment to developing sustainable mosquito control methods has made a significant mark in the industry. In essence, FourStar Microbial Products is dedicated to delivering effective, eco-friendly solutions that cater to both urban and rural needs, enhancing community safety and environmental health. For more insights on their groundbreaking products and technology, check out their detailed overview at Animas Mosquito Control District.

Research, Research, Biotechnology research
Sag Harbor, New York

4. Favus Institutional Research, LLC

Favus Institutional Research, LLC stands out in the crowded healthcare research landscape as an independent boutique that delivers unbiased and thorough analysis with a laser focus on the healthcare sector. Imagine having a trusted guide in a complex maze; that’s what Favus offers its clients by diving deep into commercial, clinical data, legal issues, reimbursement trends, and regulatory shifts without any conflicts of interest clouding the judgment. Nestled in the heart of New York, this firm has carved out a significant niche in research, hedge funds, biotechnology, diagnostics, and therapeutics. By providing high-quality, actionable insights, Favus empowers its clients to navigate the intricate dynamics of the market confidently. Their commitment to fundamental analysis and specialized expertise has earned them accolades, making them a go-to resource for institutional investors eager to make smart, informed decisions in the ever-evolving healthcare arena. With a wealth of knowledge and a commitment to objectivity, Favus Institutional Research, LLC arms its clients with the critical information necessary to reach their investment goals. This unwavering dedication to excellence and client satisfaction not only elevates their standing in the financial and healthcare communities but also positions them as a leading provider of institutional research services. To learn more about how Favus can enhance your investment strategy, check out Favus Institutional Research, LLC.

Research, Hedge funds, Biotechnology, Diagnostics, Therapeutics
Founded in 2009
New York, New York

5. Ajax Therapeutics

Ajax Therapeutics, Inc. is at the forefront of innovation in the biopharmaceutical landscape, transforming how we treat myeloproliferative neoplasms (MPNs), such as myelofibrosis. By harnessing next-generation JAK inhibitors, Ajax is not just developing treatments; they are redefining patient care. Utilizing cutting-edge computational techniques and structural biology, the company crafts highly selective therapies that zero in on the proteins responsible for MPNs, which ultimately enhances treatment effectiveness while minimizing side effects. Their standout solution, the Type II JAK2 inhibitors, is a game-changer, offering improved selectivity and efficacy compared to traditional Type I alternatives, which addresses critical gaps in existing treatment options. With headquarters in New York and Cambridge, MA, Ajax has garnered impressive support, securing a remarkable $95 million in Series C funding led by Goldman Sachs Alternatives. This capital fuels the clinical development of their pioneering Type II JAK2 inhibitor, AJ1-11095, while also propelling a robust pipeline of MPN treatments. Ajax's unique strategies, including partnerships with industry leaders like Schrödinger, Inc., position the company as a trailblazer in delivering life-changing therapies for MPN patients, igniting hope for better outcomes and quality of life. To explore Ajax Therapeutics and their groundbreaking work, visit www.ajaxtherapeutics.com.

Research, Research, Biotechnology research
Founded in 2019
New York

6. Transparency Life Sciences

Transparency Life Sciences (TLS) is not just another drug development company; it’s a trailblazer redefining the landscape of biotechnology and clinical trials through innovative open collaboration. Founded in 2012 and based in the heart of New York City, TLS harnesses the power of digital technologies to reshape how clinical trials are designed and executed. Imagine a platform where patients, doctors, and researchers come together to build clinical studies that truly meet real-world needs—this is the essence of TLS. Their unique crowdsourced web platform empowers stakeholders to contribute actively, ensuring trials are not only patient-centric but also efficient. By seamlessly integrating crowdsourcing, mobile health technology, and telemedicine, TLS is advancing drug candidates through clinical trials faster than ever, slashing costs while boosting data quality. They’ve made impressive strides, particularly in developing groundbreaking, patient-focused trials for rare diseases that often get overlooked. Recently, TLS successfully completed a $5.0 million Series A financing round to enhance its technology platform and clinical operations. This commitment to transparency and collaboration means TLS is not just improving drug development; they are accelerating the journey to market for effective therapies. Aligning with the latest FDA guidelines, TLS is earning accolades from drug development experts globally, solidifying its position as a leader in transforming the clinical trial ecosystem. For more insights on their innovative approach, check out this link.

Biotechnology, Clinical Trials, Crowdsourcing, Pharmaceutical
Founded in 2012-01-01
New York, New York, United States
For Profit

7. HistoWiz

HistoWiz, founded in 2013 and based in Brooklyn, NY, is transforming the way histopathology services are delivered, making it a game-changer in the biomedical research field. By automating and optimizing the histology process, HistoWiz allows researchers to enjoy quicker turnaround times and consistent quality that beats traditional academic core facilities. Their extensive offerings include routine hematoxylin and eosin (H&E) staining, special stains, and a full range of histology services, all powered by their innovative platform, PathologyMap. This cutting-edge tool not only guarantees a rapid 72-hour turnaround but also enhances user experience with features like slide management, collaboration, tagging, image analysis, pathology consultation, and peer review. With over 1,500 clients, including prestigious institutions like MSKCC, Stanford, Harvard, and GSK, HistoWiz empowers researchers to focus on what truly matters: groundbreaking experiments and impactful publications. Their influence spans numerous sectors, including Artificial Intelligence, Biotechnology, Health Care, and Pharmaceutical industries, significantly speeding up cancer research and drug discovery through the power of automation and AI. Additionally, HistoWiz has pioneered the first online network of pathologists, featuring over 60 board-certified experts in human and veterinary pathology, and has been cited in more than 300 peer-reviewed manuscripts—setting a new benchmark for how pathology results are shared. By delivering faster, high-quality services and promoting global collaboration, HistoWiz is an invaluable resource for researchers around the world. For more insights into the impact of histopathology services, check out this article.

Artificial Intelligence, Biotechnology, Database, Government, Health Care, Hospital, Life Science, Medical, Pharmaceutical, Veterinary
Founded in 1/1/12
Brooklyn, New York, United States
For Profit

8. Humane Genomics

Humane Genomics, an innovative biotechnology company nestled in the vibrant hub of New York City, is shaking up the landscape of cancer treatment with its cutting-edge oncolytic viral therapies. Imagine a precision-engineered virus that zeroes in on cancer cells like a heat-seeking missile—this is the essence of Humane Genomics' proprietary platform. By crafting artificial viruses specifically designed to target and obliterate cancer cells, they offer a remarkable blend of safety and effectiveness that traditional therapies often lack. Their pioneering approach not only enhances the therapeutic window but also ensures a powerful, systematic delivery, effectively addressing both primary tumors and those pesky metastases. By harnessing the power of synthetic biology and advanced computational tools, Humane Genomics has propelled forward in the biotechnology and genetics arenas, making waves especially in pediatric liver cancer through their collaboration with Texas Children's Hospital to develop targeted therapies. Being at the epicenter of the global biotech scene facilitates their mission of collaboration and innovation. In fact, preclinical studies have shown an impressive 50% reduction in tumor volume, underscoring the potential of their groundbreaking platform. With a commitment to delivering state-of-the-art, precision-designed oncolytic viral therapies, Humane Genomics is not just offering treatments; they're igniting hope for safer, more effective cancer solutions. Their relentless dedication to leveraging synthetic biology to fight cancer truly showcases their passion for advancing human health through revolutionary genetic innovations. For more insights into this transformative approach, check out this resource on oncolytic viruses.

Biotechnology, Genetics, Health Care
Founded in 1/1/19
New York, New York, United States
For Profit

9. RenovaCare

RenovaCare, Inc. is a pioneering clinical-stage biotechnology company that’s reshaping the future of healing through its innovative autologous (self-donated) stem cell therapies, particularly focusing on the body’s largest organ: the skin. At the heart of its groundbreaking approach is the CellMist™ System, which employs the patented SkinGun™ to effortlessly spray a liquid suspension of a patient’s own stem cells directly onto wounds. This revolutionary method provides a powerful alternative for those suffering from burns, chronic wounds, and scars, significantly improving healing times and reducing pain compared to traditional skin grafting. Imagine spending less time in the operating room and enjoying shorter hospital stays, all while experiencing faster recovery and better cosmetic outcomes. With the potential to become a best-in-class wound healing platform, RenovaCare is poised to set a new standard for burn treatment in a market that could exceed $1 billion in the U.S. alone. Based in the bustling heart of New York City, the company has hit impressive milestones, including conditional FDA approval for its Investigational Device Exemption (IDE) and strategic partnerships that bolster its manufacturing and regulatory efforts. By staying committed to advancing regenerative cell therapy technologies, RenovaCare is not just a player in the biotechnology, medical device, and therapeutics fields; it’s a game changer. The company is dedicated to providing innovative treatments that deliver tangible clinical benefits, ultimately aiming to reach millions of individuals worldwide who are affected by burns and wounds. For more insights on regenerative medicine, you can check out resources from the [National Institutes of Health](https://www.nih.gov).

Biotechnology, Medical Device, Therapeutics
Founded in 1983-07-14
New York, New York, United States
For Profit

10. Immunic Therapeutics

Immunic Therapeutics is a dynamic biotechnology company that is making waves in the fight against chronic inflammatory and autoimmune diseases with its innovative, orally administered small molecule therapies. Imagine a world where conditions like multiple sclerosis, ulcerative colitis, Crohn's disease, psoriasis, and celiac disease can be managed more effectively—that's the vision driving Immunic. Their standout development program, vidofludimus calcium (IMU-838), has demonstrated impressive results in phase 2 clinical trials, particularly for relapsing-remitting multiple sclerosis and moderate-to-severe ulcerative colitis. This first-in-class therapy works like a finely-tuned machine by combining neuroprotective effects with anti-inflammatory and anti-viral properties, thanks to its role as a nuclear receptor related 1 (Nurr1) activator and selective inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH). Based in the bustling heart of New York, Immunic is not just another name in the biotechnology and life sciences sectors; it’s a beacon of hope, providing new and meaningful treatment options. Furthermore, they’ve also ventured into exploring the potential of IMU-838 for COVID-19 treatment, teaming up in an investigator-sponsored phase 2 clinical trial to assess its efficacy alongside oseltamivir for patients battling moderate-to-severe COVID-19. By prioritizing patient care and harnessing the latest scientific advancements, Immunic is committed to delivering high-quality oral treatment options that aim to transform the lives of those grappling with chronic inflammatory and autoimmune diseases. For more insights into their groundbreaking work, check out their official website here.

Biotechnology, Life Science, Medical, Therapeutics
Founded in 4/1/16
New York, New York, United States
For Profit

These 10 Biotechnology companies in New York are at the forefront of innovation and growth. Their impact on the industry is profound, and they continue to drive progress and success.